Trial · NCT02564926
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Adjusted Mean Changes From Baseline in Total Body Fat Mass by DXA Scan | Dapagliflozin | -1485.69 | 95% Confidence Interval -2025.543 to -945.844 | grams | |
| Adjusted Mean Changes From Baseline in Total Body Fat Mass by DXA Scan | Glimepiride | 1096.34 | 95% Confidence Interval 556.489 to 1636.187 | grams | |
| Adjusted Mean Change in HbA1c at Week 52 | Dapagliflozin | -1.00 | 95% Confidence Interval -1.259 to -0.745 | percentages | |
| Adjusted Mean Change in HbA1c at Week 52 | Glimepiride | -0.54 | 95% Confidence Interval -0.802 to -0.287 | percentages | |
| HbA1c <7.0% at Week 52 | Dapagliflozin | Count of participants that achieved the response | 27 | Participants | |
| HbA1c <7.0% at Week 52 | Glimepiride | Count of participants that achieved the response | 22 | Participants | |
| Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52 | Dapagliflozin | -30.94 | 95% Confidence Interval -40.084 to -21.800 | mg/dL | |
| Adjusted Mean Change in Fasting Blood Sugar (FBS) at Week 52 | Glimepiride | -12.70 | 95% Confidence Interval -21.786 to -3.607 | mg/dL | |
| Adjusted Mean Change in Total Body Weight at Week 52 | Dapagliflozin | -2.4 | 95% Confidence Interval -3.104 to -1.664 | kg | |
| Adjusted Mean Change in Total Body Weight at Week 52 | Glimepiride | 1.3 | 95% Confidence Interval 0.545 to 1.984 | kg | |
| Adjusted Mean Change in Waist Circumference at Week 52 | Dapagliflozin | -2.37 | 95% Confidence Interval -3.480 to -1.253 | cm | |
| Adjusted Mean Change in Waist Circumference at Week 52 | Glimepiride | -0.16 | 95% Confidence Interval -1.271 to 0.957 | cm | |
| Adjusted Mean Change in Body Mass Index (BMI) at Week 52 | Dapagliflozin | -0.91 | 95% Confidence Interval -1.172 to -0.640 | kg/m^2 | |
| Adjusted Mean Change in Body Mass Index (BMI) at Week 52 | Glimepiride | 0.46 | 95% Confidence Interval 0.194 to 0.726 | kg/m^2 | |
| Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52 | Dapagliflozin | -2.18 | 95% Confidence Interval -5.123 to 0.766 | mmHg | |
| Adjusted Mean Change in Systolic Blood Pressure (SBP) at Week 52 | Glimepiride | 4.63 | 95% Confidence Interval 1.682 to 7.570 | mmHg | |
| Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52 | Dapagliflozin | -0.25 | 95% Confidence Interval -2.523 to 2.023 | mmHg | |
| Adjusted Mean Change in Diastolic Blood Pressure (DBP) at Week 52 | Glimepiride | 2.36 | 95% Confidence Interval 0.092 to 4.638 | mmHg | |
| Adjusted Mean Change in Visceral Adipose Tissue (VAT) Area at Week 52 | Dapagliflozin | -16.06 | 95% Confidence Interval -23.806 to -8.317 | cm^2 | |
| Adjusted Mean Change in Visceral Adipose Tissue (VAT) Area at Week 52 | Glimepiride | 1.48 | 95% Confidence Interval -6.407 to 9.377 | cm^2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02564926/results